Like many other Seeking Alpha contributors, I'm a huge fan of companies with management with proven track records in creating shareholder value. Unquestionably, Shai Novik, founder and president of Prolor Biotech has done so.
Last year I wrote that Prolor Biotech (NYSEMKT:PBTH) was a prime candidate for a buyout, based on its valuation, clinical assets, and investor Philip Frost's involvement with both Prolor and Teva (NYSE:TEVA). Although Teva turned out not to be the buyer, my original thesis played out almost exactly: Prolor was acquired by OPKO Health (NYSEMKT:OPK) earlier this year. (Frost is also the CEO and Chairman of OPKO.) For readers who bought Prolor when I wrote the article, the value has...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|